Recent Updates
Recently added Catalysts

ARO-RAGE

Phase 2

Asthma | Small molecule | Respiratory |Arrowhead Pharmaceuticals, Inc.|Last Updated: Jun 23, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials3
Total Enrollment206
FDA Designations
No designations recorded
Clinical trial landscape

ARO-RAGE · 3 trials · 1 indication

Phase 2 1Phase 1 2
NCT07241546Study of Inhaled ARO-RAGE in Allergen-induced Mild AsthmaAsthma
RECRUITING36 Analytics
PHASE2RECRUITING
Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma
Asthma
NCT0724154636
Unlock trial analytics
Study Endpoints
Primary Endpoints
Change from Baseline Over Time in Maximum Area of Reactance
Baseline through Day 58
Number of Participants with Treatment-Emergent Adverse Events (TEAEs)
From first dose of study drug through the end of study (EOS; up to 113 days or until serum soluble receptor for advance glycation end products [SRAGE] is ≥70% of baseline value, whichever is later)
Secondary Endpoints
Change from Baseline Over Time in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve
Baseline through Day 58
Change from Baseline Over Time in Maximum Change in Small Airway Reactance
Baseline through Day 58
Number of Participants with Treatment-Emergent Adverse Events
Up to Day 113 (End of Study)
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
ARO-RAGEEXPERIMENTALARO-RAGE inhalation
PlaceboPLACEBO_COMPARATORNormal saline (0.9%)
Interventions
NameTypeDescription
ARO-RAGEDRUGInhalation of nebulized solution
PlaceboDRUGCalculated volume to match active treatment by inhalation of nebulized solution
ARO-RAGE InjectionDRUGARO-RAGE injection for sc administration
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to 65 Years
SexALL
Healthy VolunteersNo
Study Sites5

Inclusion Criteria: * Clinically stable, mild atopic asthma (FEV1 ≥70% predicted) * Established allergy confirmed by positive skin prick test at screening * Willing and able to perform lung function tests and other study-related procedures * Participants of childbearing potential must consent to us...

Countries:CanadaNew ZealandAustraliaPolandSpainThailand
Unlock Eligibility Criteria
Competitive Landscape -Asthma 77 trials
CompanyTickerTrialsLead PhaseDrugs
Teva Pharmaceutical Industries Limited Sponsored ADRTEVA4PHASE3Fp/ABS, ABS
GSK plc Sponsored ADRGSK5PHASE3FF/UMEC/VI
Sanofi SA Sponsored ADRSNY7PHASE3Dupilumab
Novartis AG Sponsored ADRNVS5PHASE3QVM149, Salmeterol Xinafoate / Fluticasone Propionate, Run-In Medication
AstraZeneca PLCAZN28PHASE3Benralizumab
Generate Biomedicines, Inc.GENB3PHASE3GB-0895
Eli Lilly and CompanyLLY1PHASE2Brenipatide
Incyte CorporationINCY1PHASE2povorcitinib, ICS-LABA
Pfizer Inc.PFE1PHASE2PF-07275315
Kymera Therapeutics, Inc.KYMR1PHASE2KT-621
Upstream Bio, Inc.UPB1PHASE2Verekitug
Arrowhead Pharmaceuticals, Inc.ARWR1PHASE2ARO-RAGE
Sunshine Biopharma IncorporatedSBFM2PHASE3610
Amgen Inc.AMGN1PHASE1AMG 691
Apogee Therapeutics, Inc.APGE1PHASE1APG777
Celldex Therapeutics, Inc.CLDX1PHASE1CDX-622
Unity Health TorontoUBX1N/AUndisclosed
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
LOWJun 23, 2026NCT07241546lastUpdatePostDate: changed
LOWJun 23, 2026NCT07241546lastUpdatePostDate: changed
LOWMay 29, 2026NCT07241546lastUpdatePostDate: changed
LOWMay 29, 2026NCT07241546lastUpdatePostDate: changed
LOWMay 29, 2026NCT07241546lastUpdatePostDate: changed
LOWMay 26, 2026NCT07241546Status: NOT_YET_RECRUITING → RECRUITING
LOWMay 24, 2026NCT07241546studyFirstPostDate: changed